Merck KGaA Completes Acquisition of SpringWorks Therapeutics in $3.9 Billion Deal

SpringWorks Therapeutics US85205L1070

The journey of SpringWorks Therapeutics as a publicly traded company has concluded following its full acquisition by the German science and technology conglomerate, Merck KGaA. The transaction, finalized in July 2025, resulted in the delisting of SpringWorks' shares from the NASDAQ, highlighting the strategic value of therapies targeting rare diseases.

Merck KGaA secured the deal at a price of $47 per share, representing a significant 26% premium over the stock's trading price at the time. With an equity value of approximately $3.9 billion, the acquisition is poised to bolster the DAX-listed company's healthcare division, specifically within the rare tumors segment. The integration process is anticipated to begin contributing positively to earnings starting in 2027.

A key asset transferred in the acquisition is SpringWorks' portfolio of two FDA-approved medications, which have also recently gained European authorization.

• OGSIVEO (nirogacestat): This therapy is approved for treating desmoid tumors in adults. The European Commission granted marketing authorization for this indication in August 2025. Compelling long-term clinical data was published in October 2025, showing the objective response rate rising from 34.3% at one year to 45.7% after up to four years of treatment in the Phase 3 trial.
• GOMEKLI (mirdametinib): Approved as the first therapy for plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN) in adult and pediatric patients. European approval for this treatment followed in July 2025.

Market Exit and Strategic Rationale

The takeover was formally completed on July 1, 2025. Consequently, SpringWorks Therapeutics shares were removed from the NASDAQ exchange, with a final closing price recorded at $46.99. The company was also deleted from major indices, including the Russell 3000, and now operates as a wholly-owned subsidiary of Merck KGaA.

For Merck KGaA, this strategic move solidifies its footprint in the United States market and substantially expands its oncology and rare disease pipeline. The focus now shifts to leveraging SpringWorks' targeted therapies on a global scale to unlock their full potential.